Novartis Bolsters I-O Discovery Pipeline With Surface Oncology Deal

Novartis AG has made a new addition to its ever growing immuno-oncology portfolio, this time licensing four pre-clinical programs from Cambridge, Massachusetts-based biotech Surface Oncology, in a deal worth more than $170m.

Novartis AG has made a new addition to its ever growing immuno-oncology portfolio, this time licensing four pre-clinical programs from Cambridge, Massachusetts-based biotech Surface Oncology, in a deal worth more than $170m.

Novartis will get exclusive access to the 2014-founded company's current pipeline of cancer immunotherapies, consisting of an exclusive worldwide license...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category